Apellis Pharmaceuticals, Inc., a global biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Syfovre is the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the US and five million people worldwide.
